ABX464 First in Man, Open Label, Parallel Group, Single Ascending Dose Study.

Trial Profile

ABX464 First in Man, Open Label, Parallel Group, Single Ascending Dose Study.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Dec 2016

At a glance

  • Drugs ABX 464 (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; First in man
  • Sponsors Abivax
  • Most Recent Events

    • 20 Dec 2016 Results published in the Journal of Antimicrobial Chemotherapy
    • 30 Dec 2014 New trial record
    • 01 Dec 2014 Results published in an Abivax media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top